The Rick Hansen Institute is pleased to announce it has appointed four new members to its Board of Directors. The four are international leaders who come from diverse backgrounds including a retired high-ranking Canadian public servant, a former Paralympian, a successful entrepreneur and venture philanthropist and a chartered professional accountant with extensive experience in both the financial and not-for-profit sectors.

Where will you be October 17-18, 2014? Join the Rick Hansen Institute at the 9th Annual Working 2 Walk Science & Advocacy Symposium.

Minocyline shows promise for limiting the severity of spinal cord injuries at a fraction of time and cost of other new drug treatments, says Rick Hansen Institute

August 14, 2014 VANCOUVER - The Rick Hansen Institute (RHI) is pleased to announce an international clinical trial to test promising research that suggests minocycline may decrease the severity of acute spinal cord injury (SCI).

In February, RHI announced two new funding opportunities Preclinical SCI Research Towards Cures (PSRTC) and Emerging Interventions & Innovative Technologies (EIIT). These competitions were developed to meet the objectives of RHI's 2013 – 2018 Business Plan, to align with the areas of focus of the Cure, Care and Commercialization Programs and ultimately, help RHI move closer towards achieving its vision of a world without paralysis after spinal cord injury. RHI is pleased to announce the results of both funding competitions.

Earlier this year, as part of its Best and Brightest program, RHI partnered with the Michael Smith Foundation for Health Research (MSFHR) to support two MSFHR Scholar Awards in the field of SCI research.